11 Best Falling Stocks to Buy According to Analysts

7. Becton, Dickinson and Company (NYSE:BDX)

52 Week Range: $169.52 – $251.99

Current Share Price: $169.54

Analysts Upside Potential as of May 2: 37.43%

Number of hedge fund holders: 56

Becton, Dickinson, and Company (NYSE:BDX) is a medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. Its products are used to improve drug delivery, enhance diagnostics, and advance medical discovery research. While the stock has slid 8% year-to-date, Piper Sandler analyst Jason Bednar insists it is a Buy with a $260 price target.

The bullish stance stems from the leading force in the Healthcare Equipment & Supplies industry delivering strong Q2 2025 results. Becton, Dickinson, and Company (NYSE:BDX) delivered a 4.5% revenue growth to $5.3 billion as earnings per share totaled $3.35. Concerned by the impact of tariffs, Becton Dickinson and Company says it expects its full-year revenue to range between $21.8 billion and $21.9 billion with diluted EPS of between $14.06 and $14.34.

In addition, Becton, Dickinson, and Company (NYSE:BDX) is planning a $2.5 billion investment in the US as it looks to enhance its manufacturing capacity in response to the trade tariffs. It also plans to strengthen its market leadership and improve its product portfolio through new launches and FDA clearance.